Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) have been assigned an average rating of “Buy” from the nine research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $18.78.
A number of equities research analysts have issued reports on NBRV shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $16.00 target price on shares of Nabriva Therapeutics AG in a research report on Friday, September 1st. Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $9.25 target price for the company in a research report on Wednesday, October 11th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price (up previously from $16.00) on shares of Nabriva Therapeutics AG in a research report on Monday, August 28th. SunTrust Banks, Inc. increased their target price on shares of Nabriva Therapeutics AG from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, September 18th. Finally, Wedbush restated an “outperform” rating and set a $21.00 price target (up previously from $13.00) on shares of Nabriva Therapeutics AG in a research note on Monday, September 18th.
Shares of Nabriva Therapeutics AG (NBRV) traded up 0.45% during mid-day trading on Friday, hitting $6.69. 315,668 shares of the stock traded hands. The company’s market cap is $179.55 million. Nabriva Therapeutics AG has a 52 week low of $3.52 and a 52 week high of $14.10. The stock has a 50-day moving average of $8.37 and a 200-day moving average of $9.76.
Nabriva Therapeutics AG (NASDAQ:NBRV) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($5.83) by $5.29. The company had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $1.34 million. Analysts anticipate that Nabriva Therapeutics AG will post ($2.29) EPS for the current year.
In related news, major shareholder Hbm Healthcare Investments (Ca sold 44,231 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $10.50, for a total value of $464,425.50. Following the transaction, the insider now directly owns 2,421,367 shares in the company, valued at approximately $25,424,353.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Vivo Capital Viii, Llc bought 52,631 shares of the stock in a transaction that occurred on Monday, September 18th. The stock was purchased at an average price of $9.46 per share, for a total transaction of $497,889.26. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 57,219 shares of company stock worth $535,919 and have sold 125,816 shares worth $1,249,475. Corporate insiders own 2.75% of the company’s stock.
A number of large investors have recently bought and sold shares of NBRV. Royal Bank of Canada grew its stake in Nabriva Therapeutics AG by 19.6% in the 2nd quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after buying an additional 8,650 shares during the last quarter. Almanack Investment Partners LLC. grew its stake in Nabriva Therapeutics AG by 482.2% in the 2nd quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock valued at $1,633,000 after buying an additional 751,366 shares during the last quarter. Nationwide Fund Advisors grew its stake in Nabriva Therapeutics AG by 4.6% in the 2nd quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after buying an additional 7,924 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in Nabriva Therapeutics AG by 9.9% in the 1st quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares during the last quarter. Institutional investors and hedge funds own 50.23% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Nabriva Therapeutics AG (NBRV) Receives $18.78 Consensus Target Price from Analysts” was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2968921/nabriva-therapeutics-ag-nbrv-receives-18-78-consensus-target-price-from-analysts.html.
About Nabriva Therapeutics AG
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.